JP7665513B2 - 細胞を単離及び拡大する方法 - Google Patents

細胞を単離及び拡大する方法 Download PDF

Info

Publication number
JP7665513B2
JP7665513B2 JP2021524452A JP2021524452A JP7665513B2 JP 7665513 B2 JP7665513 B2 JP 7665513B2 JP 2021524452 A JP2021524452 A JP 2021524452A JP 2021524452 A JP2021524452 A JP 2021524452A JP 7665513 B2 JP7665513 B2 JP 7665513B2
Authority
JP
Japan
Prior art keywords
cells
population
hematopoietic tissue
tissue sample
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021524452A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022506841A5 (https=
JPWO2020095059A5 (https=
JP2022506841A (ja
Inventor
バンダリ シュリスティ
フローレンス サミュエル
ハットン アンドリュー
マシアス ルイーザ
ヌスバウマー オリバー
ソダーストロム カレ
ウーデン マーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GammaDelta Therapeutics Ltd
Original Assignee
GammaDelta Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GammaDelta Therapeutics Ltd filed Critical GammaDelta Therapeutics Ltd
Publication of JP2022506841A publication Critical patent/JP2022506841A/ja
Publication of JP2022506841A5 publication Critical patent/JP2022506841A5/ja
Publication of JPWO2020095059A5 publication Critical patent/JPWO2020095059A5/ja
Priority to JP2025064036A priority Critical patent/JP2025106453A/ja
Application granted granted Critical
Publication of JP7665513B2 publication Critical patent/JP7665513B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/24—Gas permeable parts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/99—Serum-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Clinical Laboratory Science (AREA)
  • Sustainable Development (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021524452A 2018-11-08 2019-11-08 細胞を単離及び拡大する方法 Active JP7665513B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025064036A JP2025106453A (ja) 2018-11-08 2025-04-09 細胞を単離及び拡大する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1818243.6A GB201818243D0 (en) 2018-11-08 2018-11-08 Methods for isolating and expanding cells
GB1818243.6 2018-11-08
PCT/GB2019/053166 WO2020095059A1 (en) 2018-11-08 2019-11-08 Methods for isolating and expanding cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025064036A Division JP2025106453A (ja) 2018-11-08 2025-04-09 細胞を単離及び拡大する方法

Publications (4)

Publication Number Publication Date
JP2022506841A JP2022506841A (ja) 2022-01-17
JP2022506841A5 JP2022506841A5 (https=) 2022-11-25
JPWO2020095059A5 JPWO2020095059A5 (https=) 2022-11-25
JP7665513B2 true JP7665513B2 (ja) 2025-04-21

Family

ID=64739360

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021524452A Active JP7665513B2 (ja) 2018-11-08 2019-11-08 細胞を単離及び拡大する方法
JP2025064036A Pending JP2025106453A (ja) 2018-11-08 2025-04-09 細胞を単離及び拡大する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025064036A Pending JP2025106453A (ja) 2018-11-08 2025-04-09 細胞を単離及び拡大する方法

Country Status (14)

Country Link
US (1) US12460180B2 (https=)
EP (1) EP3877510A1 (https=)
JP (2) JP7665513B2 (https=)
KR (1) KR20210111747A (https=)
CN (1) CN113423821A (https=)
AU (1) AU2019374489B2 (https=)
BR (1) BR112021008166A2 (https=)
CA (1) CA3117913A1 (https=)
EA (1) EA202190864A1 (https=)
GB (1) GB201818243D0 (https=)
IL (1) IL282901A (https=)
MX (1) MX2021005480A (https=)
PH (1) PH12021551038A1 (https=)
WO (1) WO2020095059A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
CA3145523A1 (en) 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Therapeutic uses of anti-tcr delta variable 1 antibodies
US20220290101A1 (en) 2019-08-16 2022-09-15 GammaDelta Therapeutics Limited Ex vivo gamma delta t cell populations
GB202002581D0 (en) 2020-02-24 2020-04-08 Gammadelta Therapeutics Ltd Novel antibodies
LT4269444T (lt) 2020-08-14 2024-09-25 GammaDelta Therapeutics Limited Daugiaspecifiniai anti-tcr kintamos delta 1 antikūnai
TW202246338A (zh) 2021-02-17 2022-12-01 英商適應生物治療有限公司 抗ＴＣＲδ可變1抗體
GB202105113D0 (en) 2021-04-09 2021-05-26 Gammadelta Therapeutics Ltd Novel method
KR20240040799A (ko) 2021-08-03 2024-03-28 감마델타 테라퓨틱스 엘티디 감마 델타 t 세포 및 이의 조성물의 조작
WO2023194915A1 (en) 2022-04-04 2023-10-12 Gammadelta Therapeutics Ltd Novel gene armoring
GB202204926D0 (en) 2022-04-04 2022-05-18 Gammadelta Therapeutics Ltd Method for expanding gammadelta T cells
WO2025017531A1 (en) * 2023-07-20 2025-01-23 Takeda Pharmaceutical Company Limited Grid-free methods for making gamma delta t cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007511205A (ja) 2003-10-08 2007-05-10 ウィルソン ウォルフ マニュファクチャリング コーポレイション 気体透過性物質を利用する細胞を培養する方法及び装置
JP2013524856A (ja) 2010-05-07 2013-06-20 ファイブロセル テクノロジーズ， インコーポレイテッド 自己真皮線維芽細胞の投与単位処方物
US20180312808A1 (en) 2015-10-30 2018-11-01 Cancer Research Technology Limited Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
WO2018202808A2 (en) 2017-05-03 2018-11-08 King's College, London Expansion of gamma delta t cells, compositions, and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
US7078034B2 (en) 1999-01-28 2006-07-18 Palmetto Health Alliance In vitro activated γ δ lymphocytes
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
AU2006340750B2 (en) 2005-11-28 2013-03-07 Zymogenetics, Inc. IL-21 antagonists
JP4659785B2 (ja) * 2007-06-15 2011-03-30 トヨタ自動車株式会社 内燃機関の燃料噴射制御装置
US9428567B2 (en) 2010-12-22 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University Antagonists of interleukin-2 receptor
CN103635573B (zh) 2011-05-19 2016-05-11 分子医学研究所 包含γδT细胞的淋巴细胞系、其组合物及生产方法
JP2016539929A (ja) 2013-10-25 2016-12-22 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫療法のためのポリクローナルγδＴ細胞
AU2015273501B2 (en) 2014-06-11 2021-01-21 Polybiocept Gmbh Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
WO2016081518A2 (en) 2014-11-17 2016-05-26 Adicet Bio, Inc. Engineered gamma delta t-cells
AU2016274633B2 (en) 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
US11401507B2 (en) * 2016-11-17 2022-08-02 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
BR112019013940A2 (pt) 2017-01-06 2020-02-11 Iovance Biotherapeutics, Inc. Método de tratar um câncer com uma população de linfócitos infiltrantes de tumor, processo para preparação de uma população de linfócitos infiltrantes de tumor, população de linfócitos infiltrantes de tumor, e, composição farmacêutica.
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
KR20210111746A (ko) 2018-11-08 2021-09-13 감마델타 테라퓨틱스 리미티드 세포를 단리 및 증식하는 방법
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007511205A (ja) 2003-10-08 2007-05-10 ウィルソン ウォルフ マニュファクチャリング コーポレイション 気体透過性物質を利用する細胞を培養する方法及び装置
JP2013524856A (ja) 2010-05-07 2013-06-20 ファイブロセル テクノロジーズ， インコーポレイテッド 自己真皮線維芽細胞の投与単位処方物
US20180312808A1 (en) 2015-10-30 2018-11-01 Cancer Research Technology Limited Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
WO2018202808A2 (en) 2017-05-03 2018-11-08 King's College, London Expansion of gamma delta t cells, compositions, and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RACHAEL A. CLARK; ET AL，A NOVEL METHOD FOR THE ISOLATION OF SKIN RESIDENT T CELLS FROM NORMAL AND DISEASED HUMAN SKIN，JOURNAL OF INVESTIGATIVE DERMATOLOGY，NL，2006年05月，VOL:126, NR:5，PAGE(S):1059-1070，https://www.jidonline.org/action/showPdf?pii=S0022-202X%2815%2932866-9

Also Published As

Publication number Publication date
EA202190864A1 (ru) 2021-09-14
MX2021005480A (es) 2021-11-04
WO2020095059A1 (en) 2020-05-14
PH12021551038A1 (en) 2022-01-03
AU2019374489A1 (en) 2021-05-27
US12460180B2 (en) 2025-11-04
KR20210111747A (ko) 2021-09-13
AU2019374489B2 (en) 2026-04-02
JP2022506841A (ja) 2022-01-17
US20220010276A1 (en) 2022-01-13
CN113423821A (zh) 2021-09-21
EP3877510A1 (en) 2021-09-15
CA3117913A1 (en) 2020-05-14
IL282901A (en) 2021-06-30
BR112021008166A2 (pt) 2021-08-03
GB201818243D0 (en) 2018-12-26
JP2025106453A (ja) 2025-07-15

Similar Documents

Publication Publication Date Title
JP7665513B2 (ja) 細胞を単離及び拡大する方法
JP7698672B2 (ja) ガンマデルタｔ細胞の増幅、組成物およびその使用
JP7706361B2 (ja) 細胞を単離及び拡大する方法
KR102821381B1 (ko) 비-조혈조직에 상재하는 γδ Ｔ 세포의 증식 및 이들 세포의 용도
AU738538B2 (en) Method for the production of selected lymphocytes
CN115667501B (zh) 用于分离γδT细胞的方法
EA049196B1 (ru) Способы выделения и размножения клеток
EA051032B1 (ru) Способы выделения и размножения клеток
EA048634B1 (ru) Способы выделения гамма-дельта т-клеток
BR122025001918A2 (pt) Métodos de expansão de células t gama delta, composições, seu uso e uso de células t gama delta expandidas

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231024

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250409

R150 Certificate of patent or registration of utility model

Ref document number: 7665513

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150